MedPath

IM Olanzapine Versus Haloperidol or Midazolam

Phase 4
Terminated
Conditions
Acute Agitation, Behavioural Emergency
Interventions
Registration Number
NCT02380118
Lead Sponsor
The University of Hong Kong
Brief Summary

The purpose of this study is to determine whether intramuscular olanzapine is safer (fewer adverse events) and more effective (shorter time to sedation) than conventional haloperidol or midazolam when used in the management of acute agitation in the emergency department.

Detailed Description

To address significant knowledge gaps by several means:

1. Investigate intramuscular use of sedative drugs within a predominantly Chinese population, to address this void in international literature impacting the management of acute agitation.

The multi-centre RCT will determine the safety and efficacy of intramuscular olanzapine, in comparison with conventional medicines (haloperidol or midazolam) in a three-arm comparison for the sedation of acutely agitated patients in emergency department. Specifically, we aim to determine if administration of intramuscular olanzapine (a)is more effective than sedation with intramuscular haloperidol or intramuscular midazolam alone; (b)is safer than sedation with comparison arms; (c)decreases the amount of subsequent redosing or alternative drugs required; (d)is more favourable than the haloperidol and midazolam arms with respect to safety, efficacy and adverse events.

2. Investigate potential variables leading to emergency attendance and/or admission requiring parenteral sedation. These may include patient demographics and regular medications and adherence.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
167
Inclusion Criteria
  • Emergency Department patients, requiring parenteral drug sedation (as determined by an emergency clinician) will be enrolled.
Exclusion Criteria
  • Patients will be excluded if there are

    1. known hypersensitivity or contraindication to the study drugs
    2. reversible aetiology for agitation (e.g. hypotension, hypoxia, hypoglycaemia)
    3. known pregnancy
    4. acute alcohol withdrawal
    5. patients aged>75 years.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
OlanzapineOlanzapineintramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
HaloperidolHaloperidolintramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
MidazolamMidazolamintramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.
Primary Outcome Measures
NameTimeMethod
Time to achieve adequate sedationWithin 60 minutes from drug administration

Adequate sedation is determined by a 6-point validated scale.

Secondary Outcome Measures
NameTimeMethod
AED length of stay (LOS)From Emergency Department admission to transfer or discharge from Emergency Department, an expected average of 1 hour
Total study drug doses administered; alternative drugs and doses usedFrom Emergency Department admission to transfer or discharge from AED, an expected average of 1 hour
Prolonged QTc intervalFrom Emergency Department admission to transfer or discharge from Emergency Department, an expected average of 1 hour
Adverse eventsFrom Emergency Department admission to transfer or discharge from Emergency Department an expected average of 1 hour

including airway management (jaw thrust, oral, nasal airway), need for assisted ventilation (bag/mask, intubation), oxygen desaturation \<90%, systolic BP\<90 mmHg, dystonic reactions, seizures, vomiting or aspiration

Trial Locations

Locations (6)

Pamela Youde Nethersole Eastern Hospital

🇭🇰

Hong Kong, Hong Kong

Prince of Wales Hospital

🇭🇰

Hong Kong, Hong Kong

Ruttonjee Hospital

🇭🇰

Hong Kong, Hong Kong

Tuen Mun Hospital

🇭🇰

Hong Kong, Hong Kong

Queen Mary Hospital

🇭🇰

Hong Kong, Hong Kong

United Christian Hospital

🇭🇰

Hong Kong, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath